PhaseV Teams Up with Bioforum to Streamline Clinical Trials with AI Optimization

PhaseV Partners with Bioforum: Revolutionizing Clinical Trials with AI

In a groundbreaking collaboration, PhaseV, a prominent player in the field of AI/ML for clinical development, has announced a strategic partnership with Bioforum, a leading Contract Research Organization (CRO) known for its biometric services tailored to the global clinical trials industry. This partnership is set to redefine the way clinical trials are planned and executed by integrating PhaseV’s innovative Trial Optimizer platform with Bioforum's robust service offerings, crafting a seamless, AI-enhanced pathway from protocol development to study execution.

A New Era for Clinical Trials

The healthcare landscape is witnessing a rapid transformation, especially in clinical research where the demand for efficiency, cost-effectiveness, and speed has never been more critical. As the complexity of clinical trials increases, so does the need for smarter design methodologies. Enter PhaseV's Trial Optimizer—an avant-garde solution that employs advanced artificial intelligence and machine learning techniques to simulate and evaluate millions of trial configurations in mere minutes.

This cutting-edge integration promises to empower research sponsors with the tools necessary to optimize their studies before enrollment of the first patient. By facilitating design simulations and comparisons, sponsors can determine the most effective trial configuration right from the outset, thereby increasing the likelihood of study success while simultaneously minimizing expenses.

Eliminating Inefficiencies

Historically, sponsors faced numerous challenges when trial design and execution were handled in silos. Costly delays, inefficiencies, and data discrepancies often derailed trial timelines and escalated budgets. Amir Malka, CEO and Co-founder of Bioforum, articulated these challenges stating, "Sponsors often face costly delays and inefficiencies when trial design and execution are managed separately."

By merging PhaseV’s optimization technologies into Bioforum's workflow, this partnership directly addresses these longstanding obstacles in clinical research. The integrated approach not only reduces the need for cumbersome handoffs between design and operational teams but also significantly diminishes the risk of protocol amendments, thus streamlining decision-making across various therapeutic areas.

Enhanced Capabilities for Sponsors

The collaboration between PhaseV and Bioforum is designed to cater to the demands of modern clinical trials, which require adaptability and rapid iteration. Raviv Pryluk, CEO and Co-founder of PhaseV, emphasized that sponsors are increasingly seeking ways to design studies that maximize their chances of success. Through this partnership, trial sponsors can engage in detailed scenario simulation, moving effortlessly from the design phase to execution without wasting valuable time.

One compelling example of the success associated with the PhaseV platform is evident in a recent simulation conducted for an obesity study. The platform identified a design that could reduce sample size by approximately 20% while still retaining statistical power, leading to considerable cost savings in the tens of millions and swifter completion of trials.

The Commitment to Advancing Clinical Research

PhaseV is not just about optimization; it's about transforming the clinical development landscape. The company's innovative solutions have been shown to lower trial costs by as much as 50%, shrink enrollment sizes and durations by 40%, and enhance the probability of success by over 30%. So far, PhaseV has delivered impressive results across more than 30 leading pharmaceutical, biotech, and medical device organizations spread across various therapeutic fields including neurology, oncology, immunology, gastrointestinal diseases, and rare disorders.

As they combine their strengths, PhaseV and Bioforum aim to expedite the journey of bringing groundbreaking treatments to market, ensuring that patients reap the benefits of new therapies in a timely manner.

For more insights into their innovative approaches and services, visit PhaseVTrials.com and learn more about Bioforum at bioforumgroup.com.

As the collaboration unfolds, the healthcare industry is set to witness a new era of efficiency and precision in clinical trials, firmly positioning PhaseV and Bioforum at the forefront of clinical research advancement.